Group 1 - Genuine Parts Company plans to release its fourth quarter and full-year financial results on February 18, 2025 [1] - Following the financial results release, management will host a conference call at 8:30 a.m. ET, accessible via webcast and phone [1] - The company has a vast network of over 10,700 locations across 17 countries, supported by more than 60,000 employees [2] Group 2 - Established in 1928, Genuine Parts Company is a leading global service provider of automotive and industrial replacement parts [2] - The Automotive Parts Group operates in multiple countries including the U.S., Canada, Mexico, and several European nations [2] - The Industrial Parts Group serves customers primarily in the U.S., Canada, Mexico, and Australasia [2]

GPC ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Genuine Parts Company ...

Core Insights - Carisma Therapeutics has announced positive pre-clinical data for its anti-GPC3 in vivo CAR-M therapy for hepatocellular carcinoma (HCC), developed in collaboration with Moderna [1][2][3] Group 1: Therapy Development - The anti-GPC3 CAR-M therapy demonstrates specificity for the GPC3 tumor antigen, showing potent dose-dependent cytotoxicity against GPC3+ tumor cells [2] - Systemic administration of the therapy significantly reduced tumor burden and suppressed liver metastasis in both syngeneic and humanized tumor models [2] - The therapy was well tolerated in mouse models, indicating its potential as an off-the-shelf treatment for GPC3+ solid tumors, including HCC [2] Group 2: Technological Innovation - The therapy utilizes mRNA/LNP technology to generate anti-GPC3 CAR-M cells directly in vivo, leading to significant tumor reduction in relevant pre-clinical models [3] - The successful application of the mRNA/LNP platform highlights its potential in enabling in vivo cell therapy [3] Group 3: Company Overview - Carisma Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies using its proprietary macrophage and monocyte cell engineering platform [4]

Core Insights - Carisma Therapeutics Inc. announced new pre-clinical data on its anti-GPC3 in vivo CAR-M therapy for hepatocellular carcinoma (HCC), developed in collaboration with Moderna, to be presented at the SITC Annual Meeting on November 8, 2024 [1][2][3] Company Overview - Carisma Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies, particularly utilizing engineered macrophages and monocytes to treat cancer and other serious diseases [5] Research and Development Highlights - The pre-clinical data indicates that the anti-GPC3 CAR-M therapy shows robust anti-tumor activity and represents a novel off-the-shelf approach for treating GPC3+ solid tumors, including HCC [2][3] - The therapy employs lipid nanoparticles to deliver mRNA encoding CARs, reprogramming endogenous myeloid cells in vivo [2] Presentation Details - The poster session at SITC will include the abstract titled "Pre-Clinical Efficacy of a Novel Anti-GPC3 In Vivo CAR-M for Hepatocellular Carcinoma," with publication number 329, scheduled for November 8, 2024 [4]

If you have found my strategies interesting, useful, or profitable, consider supporting my continued research by joining the Cyclical Investor's Club . It's only $400/year, and it's where I share my latest research and exclusive small-and-midcap ideas. Two-week trials are free. All stock investing is about risk vs. reward over time. If an investor isn't estimating the likely reward over a given time frame, like 5 or 10 years, and then comparing that to the inflation-adjusted risk over Cory leads the investi ...

Have you evaluated the performance of Genuine Parts' (GPC) international operations for the quarter ending September 2024? Given the extensive global presence of this auto and industrial parts distributor, analyzing the patterns in international revenues is crucial for understanding its financial strength and potential for growth. In the current global economy, which is more interconnected than ever, a company's success in penetrating international markets is crucial for its financial health and growth jour ...

Shares fell after the company lowered 2024 earnings expectations.Genuine Parts (GPC -2.59%) shares fell hard this week after the global automotive and industrial parts giant reported some discouraging news about its short-term operating trends. The stock fell 20% through early Thursday trading, according to S&P Global Market Intelligence, compared to a modest decline for the S&P 500 index.That performance gap was due to Genuine Parts' Q3 earnings update, which showed surprisingly weak sales and profit trend ...

Core Viewpoint - NAYA Biosciences has received regulatory approval to initiate clinical trials for its GPC3-targeting NK Engager bispecific antibody, NY-303, aimed at treating hepatocellular carcinoma (HCC) in patients who do not respond to first-line immunotherapy [1][2]. Group 1: Clinical Trial Updates - The company has received approval from the Israeli Ministry of Health and institutional review board clearance to start patient enrollment in up to 7 academic centers for the clinical trial of NY-303 [1]. - Patient recruitment for the Phase 1 trial is expected to begin in early 2025 at leading medical centers in Israel, including Hadassah Hospital, Sheba Medical Center, and Sourasky Medical Center [2]. - The Phase 1 trial will focus on dose-escalation, with key endpoints including safety, pharmacokinetics, activity markers, preliminary clinical efficacy, and time-to-progression [2]. Group 2: Mechanism and Efficacy of NY-303 - NY-303 is a first-in-class therapeutic candidate that targets both GPC3, an oncofetal protein on liver cancer cells, and NKp46, a receptor on natural killer cells, aiming to convert tumors from a "cold" to a "hot" state for better immunotherapy response [4]. - The dual targeting mechanism of NY-303 is designed to address the approximately 70% of patients who do not respond to current immunotherapy standards, with the potential to improve outcomes significantly [8]. Group 3: Industry Context and HCC Statistics - Hepatocellular carcinoma (HCC) is a leading cause of cancer death globally, with over 900,000 new cases annually, and the five-year survival rate for liver cancer in the U.S. is around 20% [3][5]. - Current treatment options for liver cancer include surgery, liver transplantation, targeted drugs, and immunotherapies, but the prognosis remains poor, especially for advanced-stage disease [5][6]. - There is a critical need for more effective therapies in the treatment of HCC, as recent advances in immunotherapy have not sufficiently improved survival rates for advanced cases [6].

Core Insights - The article discusses the investment position in GPC, indicating a beneficial long position through various means such as stock ownership and derivatives [1]. Group 1 - The author expresses personal opinions regarding GPC and clarifies that no compensation is received for the article, aside from Seeking Alpha [1]. - There is an emphasis on the necessity for investors to conduct their own due diligence and research before making any investment decisions [2]. - The article highlights that past performance does not guarantee future results, and no specific investment recommendations are provided [3].

For the quarter ended September 2024, Genuine Parts (GPC) reported revenue of $5.97 billion, up 2.5% over the same period last year. EPS came in at $1.88, compared to $2.49 in the year-ago quarter.The reported revenue represents a surprise of -0.14% over the Zacks Consensus Estimate of $5.98 billion. With the consensus EPS estimate being $2.44, the EPS surprise was -22.95%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine t ...